|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0033681,
umls-concept:C0078058,
umls-concept:C0079083,
umls-concept:C0144576,
umls-concept:C0201734,
umls-concept:C0205179,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0332173,
umls-concept:C0442027,
umls-concept:C0684249,
umls-concept:C1171892,
umls-concept:C1513884,
umls-concept:C1521808,
umls-concept:C1541530,
umls-concept:C1999216
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2008-4-9
|
|
pubmed:abstractText |
AZD2171 is a potent inhibitor of vascular endothelial growth factor receptors that showed broad antitumor activity in preclinical models. Doses of up to 45 mg/d of AZD2171 are tolerable when administered alone. This study evaluated escalating doses of AZD2171 in combination with standard chemotherapy in patients with advanced non-small-cell lung cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:ArnoldAndrewA,
pubmed-author:EllisPeter MPM,
pubmed-author:FRYDD,
pubmed-author:GauthierIsabelleI,
pubmed-author:GossGlenwoodG,
pubmed-author:LaurieScott ASA,
pubmed-author:PowersJeanJ,
pubmed-author:PuchalskiThomas ATA,
pubmed-author:RobertsonJaneJ,
pubmed-author:SeymourLesleyL,
pubmed-author:ShepherdFrances AFA,
pubmed-author:TuDongshengD,
pubmed-author:WalshWendyW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1871-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18398152-Administration, Oral,
pubmed-meshheading:18398152-Adult,
pubmed-meshheading:18398152-Aged,
pubmed-meshheading:18398152-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18398152-Carboplatin,
pubmed-meshheading:18398152-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18398152-Dose-Response Relationship, Drug,
pubmed-meshheading:18398152-Female,
pubmed-meshheading:18398152-Hematologic Diseases,
pubmed-meshheading:18398152-Humans,
pubmed-meshheading:18398152-Hypertension,
pubmed-meshheading:18398152-Lung Neoplasms,
pubmed-meshheading:18398152-Male,
pubmed-meshheading:18398152-Middle Aged,
pubmed-meshheading:18398152-Paclitaxel,
pubmed-meshheading:18398152-Protein-Tyrosine Kinases,
pubmed-meshheading:18398152-Quinazolines,
pubmed-meshheading:18398152-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
|
|
pubmed:affiliation |
The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa ON K1H 8L6, Canada. slaurie@ottawahospital.on.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
